Elyxium Wealth’s United Therapeutics UTHR Stock Holding History

Elyxium Wealth’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-98	Closed	-$47.8K	–	1217
2025 Q4	$47.8K	Buy	+98	New	+$45.6K	0.01%	364

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Elyxium Wealth's UTHR Position: Q1 2026 in Review

Elyxium Wealth sold out of United Therapeutics (UTHR) in Q1 2026, closing a stake of 98 shares — an estimated $47.8K sold.

Elyxium Wealth first reported a position in UTHR in Q4 2025 and held it in 1 quarter. The position peaked at $47.8K in Q4 2025. 854 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

Elyxium Wealth reported no remaining United Therapeutics position as of Q1 2026 after selling out during the quarter.
Elyxium Wealth sold 98 United Therapeutics shares in Q1 2026, an estimated $47.8K.
Elyxium Wealth first reported a position in United Therapeutics in Q4 2025 and held it in 1 quarter.
Elyxium Wealth's United Therapeutics position peaked at $47.8K in Q4 2025.
854 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Elyxium Wealth's 13F filing for Q1 2026, filed 6 May 2026.